

PATENT APPLICATION
ATTORNEY DOCKET 28110/36120B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|---------------------------------------|--|
| In re Application of: Chadwick et al. |) For: "Methods and Compositions |
| |) Relating to CD39-Like Polypeptides and |
| Serial No: R. 53(b) continuation of |) Nucleic Acids" |
| U.S.Ser. No. 09/240,639 filed January |) |
| 29, 1999 |) Group Art Unit: 1644 |
| |) |
| Filed: herewith |) Examiner: A. Decloux |

PRELIMINARY AMENDMENT

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Sir:

In the claims:

Please cancel all claims 1-18, without prejudice, and add new claims 19-31 as follows:

19. An isolated CD39L4 polynucleotide comprising the nucleotide sequence of SEQ
ID NO: 5.

20. An isolated polynucleotide encoding the amino acid sequence of SEQ ID NO: 6.

21. An isolated polynucleotide comprising a nucleotide sequence encoding a fragment
of the amino acid sequence of SEQ ID NO: 6, said fragment having phosphohydrolase activity.

22. The polynucleotide of claim 21 wherein said nucleotide sequence is a fragment
of SEQ ID NO: 5.

23. An isolated polynucleotide encoding a polypeptide having phosphohydrolase activity, said polynucleotide comprising a nucleotide sequence that has at least about 90% sequence identity to SEQ ID NO: 5.

24. An isolated polynucleotide encoding a polypeptide having phosphohydrolase activity, wherein said polynucleotide hybridizes under highly stringent conditions to the complement of SEQ ID NO: 5.

25. The polynucleotide according to any one of claims 20, 21, 23 or 24 that comprises nucleotides 247-1530, 385-450, 613-660, 745-807 or 823-888 of SEQ ID NO:5.

26. The polynucleotide according to any one of claims 19-24 that is a DNA.

27. A vector comprising the polynucleotide of any one of claims 19-24.

28. A host cell comprising the vector of claim 27.

29. A host cell genetically engineered to contain a polynucleotide encoding the amino acid sequence of SEQ ID NO: 6 in operative association with a regulatory sequence that controls expression of the polynucleotide in the host cell.

30. A method of making a CD39L4 polypeptide comprising the steps of culturing the host cell of claim 28 in suitable culture medium and isolating the polypeptide from the cell or the culture medium.

31. A method of making a CD39L4 polypeptide comprising the steps of culturing the host cell of claim 29 in suitable culture medium and isolating the polypeptide from the cell or the culture medium.

REMARKS

Support for the claims is found throughout the specification, including in the original claims. Claims 20 and 25 correspond to original claim 1. Claims 27-29 correspond to original claims 4-7. Support for the recitation of SEQ ID NO: 5 and specific nucleotides thereof, hybridization to the complement of SEQ ID NO: 5 and fragments (truncations) of SEQ ID NO: 6 in claims 19, 22, 24 and 25 is found, e.g., at page 3, line 29 through page 4, line 11, page 20, lines 2-5,. Support for the recitation of 90% identity in claim 23 is found, e.g., at page 25, lines 18-25. If telephonic discussions with the undersigned would expedite allowance, the Examiner is invited to contact the undersigned at the number below.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By: Li Hsien Rin Laures

Li-Hsien Rin-Laures, M.D.
Registration No. 33,547
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

July 13, 2001